ChiCTR-TRC-13004194 版本V1.1 版本创建时间2016/08/06 21:03:18 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-TRC-13004194 

最近更新日期:

Date of Last Refreshed on:

2016-08-06 21:02:46 

注册时间:

Date of Registration:

2013-10-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

在甲状腺手术中比较舒芬太尼,地佐辛,曲马多的术后早期临床镇痛效果

Public title:

The Comparison of The Effect of Postoperative Early Analgesia with Tramadol, Sufentanil and Dezocine on Thyroid Surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

在甲状腺手术中比较舒芬太尼,地佐辛,曲马多的术后镇痛效果

Scientific title:

Comparison of The Effect of Postoperative Pain with Tramadol, Sufentanil and Dezocine on Thyroid Surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

侯丽娜 

研究负责人:

韩非 

Applicant:

Lina Hou 

Study leader:

Fei Han 

申请注册联系人电话:

Applicant telephone:

+86 18704658552

研究负责人电话:

Study leader's
telephone:

+86 18686857197

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

475074788@qq.com

研究负责人电子邮件:

Study leader's E-mail:

810869427@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

哈尔滨南岗区保健路肿瘤医院麻醉科

研究负责人通讯地址:

哈尔滨南岗区保健路肿瘤医院麻醉科

Applicant address:

Department of Anesthesiology, Tumor Hospital, Bao jian Road, Harbin

Study leader's address:

Department of Anesthesiology, Tumor Hospital, Bao jian Road, Harbin

申请注册联系人邮政编码:

Applicant postcode:

150000

研究负责人邮政编码:

Study leader's postcode:

150000

申请人所在单位:

哈尔滨医科大学附属第三医院

Applicant's institution:

Third Affiliated Hospital of Harbin Medical University

研究负责人所在单位:

哈尔滨医科大学附属第三医院

Affiliation of the Leader:

Third Affiliated Hospital of Harbin Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY2013-06

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

哈尔滨医科大学附属肿瘤医院

Name of the ethic committee:

Affiliated Tumor Hospital of Harbin Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2014-01-08 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

哈尔滨医科大学附属第三医院

Primary sponsor:

Third Affiliated Hospital of Harbin Medical University

研究实施负责(组长)单位地址:

哈尔滨医南岗区保健路肿瘤医院麻醉科

Primary sponsor's address:

Department of Anesthesiology, Tumor Hospital, Bao Jian Road, Harbin

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

黑龙江

市(区县):

哈尔滨

Country:

China

Province:

Heilongjiang

City:

Harbin

单位(医院):

哈尔滨医科大学附属第三医院

具体地址:

Institution
hospital:

Third Affiliated Hospital of Harbin Medical University

Address:

经费或物资来源:

药物由哈尔滨医科大学附属第三医院麻醉科提供

Source(s) of funding:

study drugs are provided by the Third Affiliated Hospital of Harbin Medical University

研究疾病:

镇痛药物的研究  

Target disease:

The Analgesic of Research

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

比较三种镇痛药术后早期镇痛效果  

Objectives of Study:

Comparising the effect of postoperative early analgesia with three analgesic

药物成份或治疗方案详述:

舒芬太尼,曲马多,地佐辛 

Description for medicine or protocol of treatment in detail:

sufentanil,tramadol,decocine 

纳入标准:

年龄在18到70岁,ASA I 到II级的做甲状腺手术的病人。

Inclusion criteria

Ninety consenting adult patients (aged 18-70 years) ASA physical status I and II, scheduled for thyroid surgery are admitted to the study.

排除标准:

排除有严重神经及循环系统疾病的病人,肝肾功能衰竭的病人,孕妇,长期服用镇痛药的病人,阿片类药物禁忌症(过敏,支气管哮喘,重症肌无力)

Exclusion criteria:

Exclusive criteria includes known severe neurological, cardiovascular disease, hepatic and renal dysfunction, pregnancy, a long history of taking kinds of analgesic, contraindication of the opioid (a history of hypersensitivity, bronchial asthma, myasthenia gravis).

研究实施时间:

Study execute time:

From 2014-01-10 00:00:00 To 2014-04-10 00:00:00  

征募观察对象时间:

Recruiting time:

From 2014-01-10 00:00:00 To 2014-04-10 00:00:00

干预措施:

Interventions:

组别:

S组

样本量:

30

Group:

group S

Sample size:

干预措施:

舒芬太尼

干预措施代码:

Intervention:

sufentanil

Intervention code:

组别:

T组

样本量:

30

Group:

group T

Sample size:

干预措施:

曲马多

干预措施代码:

Intervention:

tramadol

Intervention code:

组别:

D组

样本量:

30

Group:

group D

Sample size:

干预措施:

地佐辛

干预措施代码:

Intervention:

decocine

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

黑龙江 

市(区县):

哈尔滨 

Country:

China

Province:

Heilongjiang

City:

Harbin

单位(医院):

哈尔滨医科大学附属第三医院 

单位级别:

三甲医院 

Institution
hospital:

Third Affiliated Hospital of Harbin Medical University

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

疼痛评分

指标类型:

主要指标

Outcome:

VAS Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

实验设计者用随机表格

Randomization Procedure (please state who generates the random number sequence and by what method):

Experiment designer use random digital watch

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Not stated

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not stated

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Not stated

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Not stated

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2014-01-24 00:00:00